TTI-101 oral / StemMed, Tvardi Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TTI-101 oral / Tvardi Therap
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
100
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
03/25
NCT06141031: Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer

Recruiting
1/2
35
US
TTI-101
University of Colorado, Denver, Tvardi Therapeutics, Incorporated
Pancreatic Cancer
09/27
09/28
REVERT, NCT05384119: Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Completed
1/2
6
US
TTI-101, Palbociclib, Ibrance ®, Aromatase inhibitor (AI), fulvestrant, ribociclib
Tvardi Therapeutics, Incorporated
Breast Cancer
04/24
04/24
NCT05440708: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Recruiting
1/2
166
US
TTI-101, Pembrolizumab, Keytruda®, Atezolizumab, Tecentriq®, Bevacizumab, Avastin®
Tvardi Therapeutics, Incorporated
Hepatocellular Carcinoma
03/25
03/25

Download Options